Ubs Oconnor LLC Chemo Centryx, Inc. Call Options Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CCXI
# of Institutions
6Shares Held
66.3KCall Options Held
0Put Options Held
0-
S. Muoio & Co. LLC New York, NY58KShares$03.96% of portfolio
-
Sarissa Consulting LLC Santa Monica, CA8KShares$00.43% of portfolio
-
Wipfli Financial Advisors Llc,216Shares$00.0% of portfolio
-
Exane Derivatives92Shares$00.0% of portfolio
-
Four Thought Financial, LLC Venice, FL24Shares$00.0% of portfolio
About ChemoCentryx, Inc.
- Ticker CCXI
- Exchange NASDAQ
- Shares Outstandng 71,919,696
- Market Cap $3.68M
- Description
- ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...